TY - JOUR
T1 - WHO International Standards for antibodies to HPV6 HPV11 HPV31 HPV33 HPV45 HPV52 and HPV58
AU - the collaborative study participants
AU - Kemp, Troy J.
AU - Panicker, Gitika
AU - Eklund, Carina
AU - Nie, Jianhui
AU - Wang, Youchun
AU - Beddows, Simon
AU - Rigsby, Peter
AU - Huang, Weijin
AU - Dillner, Joakim
AU - Unger, Elizabeth R.
AU - Pinto, Ligia A.
AU - Wilkinson, Dianna E.
AU - Carter, Jody
AU - Galloway, Denise
AU - Panwar, Kavita
AU - Xu, Nan
AU - Zhou, Lingyun
AU - Zhou, Chenliang
AU - Liu, Ge
AU - Xia, Ningshao
AU - Li, Shaowei
AU - Rajanathan, T. M.Chozhavel
AU - Müller, Martin
AU - Toh, Zheng Quan
AU - Licciardi, Paul
N1 - Publisher Copyright:
© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Previously established World Health Organization (WHO) International Standards (IS) for anti-HPV16 and HPV18 antibodies are used to harmonize results across human papillomavirus (HPV) serology assays. Here, we present an international collaborative study to establish ISs for antibodies against HPV6 (NIBSC code 19/298), HPV11 (20/174), HPV31 (20/176), HPV33 (19/290), HPV45 (20/178), HPV52 (19/296) and HPV58 (19/300). The candidate standards were prepared using sera from naturally infected individuals. Each candidate was shown to be monospecific for reactivity against its indicated HPV type except for the HPV11 candidate, which was also reactive against other types. Expression of antibody levels relative to the relevant candidate IS reduced inter-laboratory variation allowing greater comparability between laboratories. Based on these results, the WHO Expert Committee on Biological Standardization established each of the 7 candidates as the 1st IS for antiserum to its indicated HPV type for use in the standardization of HPV pseudovirion-based neutralization and antibody-binding assays.
AB - Previously established World Health Organization (WHO) International Standards (IS) for anti-HPV16 and HPV18 antibodies are used to harmonize results across human papillomavirus (HPV) serology assays. Here, we present an international collaborative study to establish ISs for antibodies against HPV6 (NIBSC code 19/298), HPV11 (20/174), HPV31 (20/176), HPV33 (19/290), HPV45 (20/178), HPV52 (19/296) and HPV58 (19/300). The candidate standards were prepared using sera from naturally infected individuals. Each candidate was shown to be monospecific for reactivity against its indicated HPV type except for the HPV11 candidate, which was also reactive against other types. Expression of antibody levels relative to the relevant candidate IS reduced inter-laboratory variation allowing greater comparability between laboratories. Based on these results, the WHO Expert Committee on Biological Standardization established each of the 7 candidates as the 1st IS for antiserum to its indicated HPV type for use in the standardization of HPV pseudovirion-based neutralization and antibody-binding assays.
UR - http://www.scopus.com/inward/record.url?scp=85206936931&partnerID=8YFLogxK
U2 - 10.1038/s41541-024-00949-2
DO - 10.1038/s41541-024-00949-2
M3 - Article
AN - SCOPUS:85206936931
SN - 2059-0105
VL - 9
JO - npj Vaccines
JF - npj Vaccines
IS - 1
M1 - 165
ER -
